UCB, Advent International and Avista Capital Partners last week announced they have entered into a definitive agreement providing for the acquisition of UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals, by Advent and Avista.
A national survey from Rite Aid and National Foundation for Infectious Diseases released Monday found that the majority of adult women living in the United States do not believe they are up to date on vaccinations to protect against many preventable diseases.
Sandoz last week announced the launch of a generic version of cyclophosphamide injection, USP. Sandoz is launching the drug through collaboration with Jiangsu Hengrui Medicine Co., which owns the product's abbreviated new drug application.
Across the front-end, CVS Health is in the midst of enhancing its digital capabilities. That , along with insight into the impact of its exit from the tobacco business, was the message Tuesday morning during the company's third-quarter conference call.
Tailwinds from specialty pharmacy and increased generic utilization lifted CVS Health up on Tuesday, as the company posted net revenues of $35 billion, representing an increase of 9.7% for the three months ended Sept. 30.
Research shows that 140 million American adults (about 65%) are recommended for behavioral weight-loss treatment, with 83% of those (or 116 million) considered for pharmacotherapy, according to a report released by The Obesity Society on Monday.
As many as 62% of attendees at the Academy of Integrative Health & Medicine annual conference this week said that the most important factor in stopping Ebola in the United States is controlling the virus and caring for afflicted patients in West Africa.
The affiliated companies of Community Care of North Carolina, along with GlaxoSmithKline and the UNC Eshelman School of Pharmacy, on Thursday announced their intent to develop, implement and test new approaches to care delivery.
Independent community pharmacies are increasingly providing services to support patient medication adherence and set a new record high in the proportion of prescriptions filled with typically lower-cost generic drugs.
In the wake of an Oct. 21 blogpost on Health Affairs, “The $500 Billion Medicare Slowdown: A Story About Part D,” Ralph Neas, president and CEO of the Generic Pharmacuetical Association, issued the following statement.